Lv61
2108 积分 2025-03-04 加入
Safety considerations for cereblon-recruiting targeted protein degraders
22天前
已完结
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
1个月前
已完结
The role of the efflux transporter, P-glycoprotein, at the blood-brain barrier in drug discovery
1个月前
已完结
Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse
1个月前
已完结
Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations
1个月前
已完结
Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
3个月前
已完结
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
4个月前
已完结
Structural and Physicochemical Features of Oral PROTACs
4个月前
已完结
Correction to "Closing the Design-Make-Test-Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability"
5个月前
已完结
Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs
5个月前
已完结
皖公网安备34019202002308
